Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Vincenzo Guarini
Observed name:
V. Guarini
Institutions:
Hospital Universitario Fundación Jiménez Díaz,
Ospedale Vito Fazzi,
Instituto de Investigación Sanitaria Fundación Jiménez Díaz,
Universidad Autónoma de Madrid
Observed institutions:
University of Salento,
Hospital Universitario Fundación Jiménez Díaz,
Candiolo Cancer Institute,
Ospedale Vito Fazzi,
Fondazione IRCCS Istituto Nazionale dei Tumori,
Instituto de Investigación Sanitaria Fundación Jiménez Díaz,
Universidad Autónoma de Madrid
show all 7
ORCID:
0009-0003-3879-2410
Observed ORCID:
0009-0003-3879-2410
OpenAlex ID:
A5038188097
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials
2020
·
Giovanni Fucà
, Vincenzo Guarini
, et al.
·
British Journal of Cancer
·
479
The Landscape of Actionable Gene Fusions in Colorectal Cancer
2019
·
Filippo Pagani
, Giovanni Randon
, et al.
·
International Journal of Molecular Sciences
·
60
PDF
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden
2020
·
Filippo Pietrantonio
, Fotios Loupakis
, et al.
·
The Oncologist
·
52
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2019
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
·
Clinical Cancer Research
·
32
Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials
2020
·
Salvatore Corallo
, Giovanni Fucà
, et al.
·
The Oncologist
·
28
The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer
2021
·
Giovanna Chilà
, Vincenzo Guarini
, et al.
·
Drug Design Development and Therapy
·
23
PDF
Bioimpedentiometry parameters used as indicators of frailty and malnutrition: association between G8 score and Phase angle (PHA) in elderly cancer patients
2023
·
Silvana Leo
, Fabiana Marinelli
, et al.
·
Aging Clinical and Experimental Research
·
3
Overview of the multidisciplinary team activity in patients with hepatocellular carcinoma and their survival outcomes
2025
·
V. Guarini
, C. Garzòn
, et al.
·
ESMO Gastrointestinal Oncology
·
1
PDF
Supplementary Appendix from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2023
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
Supplementary Table S1 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2023
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
Supplementary Figure S7 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2023
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
Supplementary Figure S2 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2023
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
Supplementary Figure S4 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2023
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
Supplementary Figure S8 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2023
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
Supplementary Table S2 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2023
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
Supplementary Figure Legends from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2023
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
Supplementary Figure S1 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2023
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
PDF
Supplementary Figure S6 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2023
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
Supplementary Figure S5 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2023
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
Supplementary Figure S3 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2023
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
PDF
Supplementary Appendix from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2023
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
PDF
Supplementary Figure S3 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2023
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
Supplementary Figure S1 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2023
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
Supplementary Figure S2 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2023
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
PDF
Data from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2023
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
Show more works
View as search
Works count:
28
Citation count:
678
H-index:
6
I10-index:
6
Year
Topic
Type